Cheng Shiming, deputy director of the Center for Tuberculosis Control of China CDC, revealed during the investigation in Guangzhou recently that according to the upcoming “13th Five-Year Plan†for tuberculosis prevention and control, by 2020, 100% of municipal-level designated medical institutions need to have drug susceptibility Test, strain identification and molecular biology diagnostic capabilities, 80% of the central and central, 70% of the western counties need to have the ability to conduct molecular biology testing.
Analysts believe that at present, more than 3,000 county-level medical institutions in China have almost no molecular biology testing capability for tuberculosis, which is a rare opportunity for enterprises engaged in new diagnostic technologies for tuberculosis. A rough estimate, according to the current market price of molecular diagnostic instruments of 150,000 yuan / Taiwan, and the average annual capacity of 1000 reagents per instrument, the market capacity will reach 600 million yuan a year, and the reagents are sold in the vaccine. It will continue to grow before widespread adoption.
New technologies such as molecular diagnostics will be promoted
"Before 2020, there will be no new tuberculosis vaccines to be marketed. Accelerating the new diagnostic technology for tuberculosis is the focus of tuberculosis prevention. At the same time, new diagnostic tools will gradually be included in the scope of primary health insurance, and will accelerate the supply of new diagnostic reagents." Shi Ming pointed out.
Tuberculosis prevention and control has always been a difficult problem in the medical field. One of the main reasons is the lack of accurate and effective pathogen laboratory diagnostic methods. The commonly used detection method in China is the sputum smear method, which has a detection capacity of only 15%, which is easy to cause the patient to miss the test; and the detection period of the sputum culture method as the diagnostic diagnosis standard is up to a month, which may delay the optimal treatment period of the patient.
To this end, the State has made efforts to promote the research and development and industrialization of new diagnostic technologies for tuberculosis in the "12th Five-Year" Science and Technology Major Special Project - Infectious Disease Prevention and Control, and strive to control the scope of disease and disease from the source and significantly reduce the burden of treatment. Among them, the constant temperature PCR amplification technology represented by Dio Bio is an important focus in practice. The constant temperature PCR amplification technology has the characteristics of high efficiency, low cost, simple equipment and convenient operation. It is especially suitable for rapid screening of comprehensive medical institutions and the promotion and use of county-level grassroots disease control units.
We have not only conventional Honey but also organic honey, which have certified by BCS German. The main type is organic polyflora honey, organic acacia honey and organic vitex honey, which come from the northeast of China and Northwest of China. We supply transaction issued by BCS GERMAN for each lot when export.
Organic Polyflora Honey,Organic Acacia Honey,Organic Vitex Honey,Bee Honey,Vitex Honey
Easy Food (Jiaxing) Co., Ltd. , https://www.jxeasyfood.com